Cardiff Oncology, Inc. announced that it will be holding a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT in San Diego to discuss their financial results for the first quarter ended March 31, 2024 and provide updates on their clinical programs targeting various indications such as colorectal cancer, pancreatic cancer, small cell lung cancer, and triple negative breast cancer.
During the call, the company will also discuss their lead asset, onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care therapeutics to target tumor vulnerabilities and deliver superior clinical benefit. Individuals interested in listening to the live conference call can do so by using the webcast link in the “Investors” section of the company’s website. A replay of the call will be available in the investor relations section on the website following its completion.
For more information about Cardiff Oncology and their clinical programs, visit their website at https://www.cardiffoncology.com. For any inquiries, please contact James Levine, the Chief Financial Officer of Cardiff Oncology at 858-952-7670 or via email at jlevine@cardiffoncology.com. For investor inquiries, reach out to Kiki Patel from Gilmartin Group at 332-895-3225 or email Kiki@gilmartinir